n-(3-(Aminomethyl)phenyl)-N-methylmethanesulfonamide, 95%, 250mg

Fmoc-Val-Cit-PAB, 5g

(S)-1-(2-Amino-6-fluorophenyl)pyrrolidin-3-ol, 95.0%, 1g

Methyl 3-(3-bromophenyl)propanoate, 95.0%, 500g

Nazartinib, 100mg

6-Methyl-2,4-dioxo-3-phenyl-1h,2h,3h,4h-furo[2,3-d]pyrimidine-5-carboxylic acid, 97%, 250mg

2-Chloro-4-nitroanisole, 98.0%, 100g

9-([1,1'-Biphenyl]-4-yl)-3-bromo-9H-carbazole, 95.0%, 100g

Acetato de mercurio(II), mínimo 99 %, pa, ACS, 50 g, envase de vidrio

2-Ethyl-2-hexenal, 95.0%, 25g

4-bromo-2-fluoro-2'-(3-pyrrolinomethyl) benzophenone, 97.0%, 1g

(S)-benzyl 2-(5-bromo-1H-indole-3-carbonyl)pyrrolidine-1-carboxylate, 97%, 5g

4-cloro-1-naftol, 5 g